Azurity Pharma Inc v. Aurobindo Pharma Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Azurity Pharmaceuticals, Inc. (Delaware)
  • Defendant: Aurobindo Pharma Limited (Republic of India)
  • Plaintiff's Counsel: Potter Anderson & Corroon LLP
• Case Identification: 1:26-cv-00785, D. Del., 07/01/2026
• Venue Allegations: Venue is alleged to be proper because the defendant is a foreign corporation not residing in any U.S. district and may therefore be sued in any judicial district. The complaint also alleges the district is a likely destination for the accused product.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Plaintiff's ZONISADE® product constitutes an act of infringement of three U.S. patents covering oral suspension formulations of zonisamide.
• Technical Context: The technology concerns liquid oral suspension formulations of the anticonvulsant drug zonisamide, developed to serve patient populations, such as children or the elderly, who have difficulty swallowing solid dosage forms like tablets or capsules.
• Key Procedural History: This lawsuit was filed under the Hatch-Waxman Act, triggered by a notice letter from Aurobindo informing Azurity of its ANDA submission seeking FDA approval to market a generic version of ZONISADE® before the expiration of the patents-in-suit. The patents are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book").

Case Timeline

Date	Event
2017-08-19	Earliest Priority Date for '456, '333, and '179 Patents
2022-10-25	'456 Patent Issued
2022-12-20	'333 Patent Issued
2025-12-09	'179 Patent Issued
2026-05-18	Aurobindo Notifies Azurity of ANDA Submission
2026-07-01	Complaint Filed
2038-08-18	Patents-in-Suit Expiration Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,478,456 - "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof"

• Patent Identification: U.S. Patent No. 11,478,456, "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof," issued October 25, 2022.

The Invention Explained

• Problem Addressed: The patent's background explains that the anticonvulsant drug zonisamide was commercially available only in solid dosage forms like capsules and tablets '456 Patent, col. 4:9-11 This presents a challenge for patients who are unable to swallow solid forms, such as "children and the seriously ill persons" '456 Patent, col. 4:11-13
• The Patented Solution: The invention provides a stable and palatable liquid oral suspension of zonisamide '456 Patent, col. 4:17-20 This is achieved through a specific formulation that includes zonisamide as the active ingredient, along with a combination of pharmaceutically acceptable excipients. These include a dual-component suspending system, buffering agents to control pH, preservatives to prevent microbial growth, and sweetening agents to improve taste '456 Patent, abstract '456 Patent, col. 4:21-27 The detailed description provides an exemplary formulation in Table 1 '456 Patent, col. 7, Table 1
• Technical Importance: The development of a stable liquid formulation of zonisamide provides an essential alternative for administering the medication, potentially improving treatment compliance and access for epileptic patients with dysphagia '456 Patent, col. 3:1-7

Key Claims at a Glance

• The complaint asserts infringement of one or more claims of the patent Compl. ¶32 Independent claim 1 is a method of treatment claim and is representative of the patent's scope.
• The essential elements of independent claim 1 include:
  • A method of treating seizures by administering a liquid oral pharmaceutical suspension comprising: zonisamide in an amount of about 20 mg/mL;
  • a suspending agent comprising about 2 mg/mL to about 3.5 mg/mL xanthan gum and about 20 mg/mL of a combination of microcrystalline cellulose and sodium carboxymethylcellulose;
  • one or more buffering agents;
  • one or more pharmaceutically acceptable excipients, including a preservative;
  • wherein the suspension has a pH of 3.5 to 5.0; and
  • wherein the suspension is stable for at least 6 months when stored at 40° C. and 25% relative humidity. '456 Patent, col. 12:1-24
• The complaint does not explicitly reserve the right to assert dependent claims, though such a reservation is standard practice.

U.S. Patent No. 11,529,333 - "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof"

• Patent Identification: U.S. Patent No. 11,529,333, "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof," issued December 20, 2022.

The Invention Explained

• Problem Addressed: Similar to its family member, the '333 Patent addresses the lack of a liquid oral dosage form for the anticonvulsant zonisamide, which limits its use in patients who cannot swallow solid pills '333 Patent, col. 3:1-4
• The Patented Solution: The patent discloses a pharmaceutical composition for a liquid oral suspension of zonisamide '333 Patent, abstract The solution relies on a specific combination of excipients, including a suspending system, buffering agents, and a preservative, to create a formulation that is stable and suitable for oral administration '333 Patent, col. 4:15-27 The formulation details are similar to those in the '456 Patent '333 Patent, col. 8, Table 1
• Technical Importance: The invention provides a tangible pharmaceutical product that makes zonisamide therapy accessible to a broader patient population, including pediatric and geriatric patients '333 Patent, col. 4:5-15

Key Claims at a Glance

• The complaint asserts infringement of one or more claims of the patent Compl. ¶38 Independent claim 1 is a composition claim and is representative.
• The essential elements of independent claim 1 include:
  • A liquid oral pharmaceutical suspension comprising: zonisamide in an amount of about 20 mg/mL;
  • a suspending agent comprising about 2 mg/mL to about 3.5 mg/mL xanthan gum and about 20 mg/mL of a combination of microcrystalline cellulose and sodium carboxymethylcellulose;
  • one or more buffering agents; and
  • one or more pharmaceutically acceptable excipients, including a preservative;
  • wherein the suspension has a pH of 3.5 to 5.0; and
  • wherein the composition is stable for at least 6 months when stored at 40° C. and 25% relative humidity. '333 Patent, col. 12:1-21

U.S. Patent No. 12,491,179 - "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof"

• Patent Identification: U.S. Patent No. 12,491,179, "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof," issued December 9, 2025 Compl. ¶21
• Technology Synopsis: As a continuation of the same patent family, the '179 Patent is also directed to solving the problem of administering zonisamide to patients who cannot take solid dosage forms '179 Patent, col. 3:1-10 It claims a stable liquid oral pharmaceutical suspension containing zonisamide and a specific set of excipients, including buffering agents, preservatives, and sweeteners, to ensure product stability and palatability '179 Patent, abstract '179 Patent, col. 12:1-25
• Asserted Claims: The complaint alleges infringement of "one or more claims" Compl. ¶42 Independent claim 1 is a stable liquid oral pharmaceutical suspension.
• Accused Features: The complaint alleges that Aurobindo's proposed generic zonisamide oral suspension, as described in its ANDA No. 221557, will infringe the patent Compl. ¶29 Compl. ¶42

III. The Accused Instrumentality

• Product Identification: The accused instrumentality is Aurobindo's proposed generic zonisamide oral suspension, which is the subject of ANDA No. 221557 and referred to in the complaint as the "Aurobindo ANDA Product" Compl. ¶26
• Functionality and Market Context: The complaint alleges that Aurobindo's ANDA filing represents to the FDA that its proposed product is a generic version of Azurity's ZONISADE® product Compl. ¶26 As such, the Aurobindo ANDA Product is alleged to have the same active ingredient (zonisamide), dosage form (oral suspension), strength, and route of administration as ZONISADE®, and to be bioequivalent to it Compl. ¶29 ZONISADE® is an FDA-approved anticonvulsant used as adjunctive therapy for partial onset seizures Compl. ¶11 Aurobindo intends to commercially manufacture and sell its product in the U.S. upon receiving FDA approval Compl. ¶27
• Visual Evidence: No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint's infringement theory is based on the statutory act of infringement created by 35 U.S.C. § 271(e)(2)(A), which makes the submission of an ANDA for a generic drug an act of infringement if the generic drug would infringe a patent upon its commercialization. The complaint alleges that because Aurobindo's ANDA product is represented as bioequivalent to ZONISADE®, it will necessarily meet the limitations of the asserted claims.

U.S. Patent No. 11,478,456 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of treating seizures... comprising administering... a liquid oral pharmaceutical suspension	The Aurobindo ANDA Product is intended for use as an anticonvulsant and is an oral suspension formulation.	¶29	col. 12:1-4
zonisamide in an amount of about 20 mg/mL	The complaint alleges the ANDA product has the same active ingredient and strength as the branded product.	¶29	col. 12:4-5
a suspending agent comprising about 2 mg/mL to about 3.5 mg/mL xanthan gum and about 20 mg/mL of a combination of microcrystalline cellulose and sodium carboxymethylcellulose	The ANDA product is alleged to be a bioequivalent formulation, which suggests it contains the necessary excipients to match the branded product's characteristics.	¶29	col. 12:6-10
one or more buffering agents	The ANDA product is alleged to be a bioequivalent formulation.	¶29	col. 12:11
one or more pharmaceutically acceptable excipients... [comprising] a preservative	The ANDA product is alleged to be a bioequivalent formulation.	¶29	col. 12:12-14
wherein the liquid oral pharmaceutical suspension has a pH of 3.5 to 5.0	The ANDA product is alleged to be bioequivalent, suggesting its physical and chemical properties, like pH, are the same.	¶29	col. 12:18-19

U.S. Patent No. 11,529,333 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A liquid oral pharmaceutical suspension, comprising: zonisamide in an amount of about 20 mg/mL	The complaint alleges the Aurobindo ANDA Product has the same active ingredient and strength as the branded product.	¶29	col. 12:2-3
a suspending agent comprising about 2 mg/mL to about 3.5 mg/mL xanthan gum and about 20 mg/mL of a combination of microcrystalline cellulose and sodium carboxymethylcellulose	The ANDA product is alleged to be a bioequivalent formulation, which suggests it contains the necessary excipients to match the branded product's characteristics.	¶29	col. 12:4-8
one or more buffering agents	The ANDA product is alleged to be a bioequivalent formulation.	¶29	col. 12:9
one or more pharmaceutically acceptable excipients... [comprising] a preservative	The ANDA product is alleged to be a bioequivalent formulation.	¶29	col. 12:10-12
wherein the liquid oral pharmaceutical suspension has a pH of 3.5 to 5.0	The ANDA product is alleged to be bioequivalent, suggesting its physical and chemical properties, like pH, are the same.	¶29	col. 12:16-17

• Identified Points of Contention:
  • Scope Questions: The primary point of contention will be a comparison of the specific formulation in Aurobindo's confidential ANDA to the claimed elements. A key question will be whether Aurobindo's formulation uses the exact components in the specific concentration ranges claimed. For instance, does the term "about 20 mg/mL" encompass the precise concentration of zonisamide in the ANDA product?
  • Technical Questions: The infringement analysis will turn on factual questions resolvable only after discovery of the ANDA's contents. A central question is whether the excipients used by Aurobindo, particularly its suspending agent system, are the same as or equivalent to the specific combination of xanthan gum and microcrystalline cellulose/sodium carboxymethylcellulose required by the claims.

V. Key Claim Terms for Construction

Because the complaint is filed pre-discovery and lacks the specifics of the accused formulation, claim construction will be pivotal. Practitioners may focus on terms that define the boundaries of the claimed formulation.

• The Term: "about"

• Context and Importance: This term modifies all key concentration and range limitations in the claims (e.g., "about 20 mg/mL," "about 2 mg/mL to about 3.5 mg/mL"). The interpretation of "about" will be critical in determining whether Aurobindo's specific formulation, if it deviates even slightly from the recited values, falls within the scope of the claims. Practitioners may focus on this term because, in formulation patents, infringement can hinge on very small quantitative differences.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The patentee's consistent use of "about" when reciting numerical values suggests an intention to not be strictly limited to the exact numbers, but to include values that are approximately the same and achieve the same result '456 Patent, col. 12:4-8
  • Evidence for a Narrower Interpretation: The specification provides an exemplary formulation with high precision (e.g., "Zonisamide 20.00 mg/ml," "Xanthan gum 3.50") '456 Patent, col. 7, Table 1 A party may argue that these precise examples inform the meaning of "about," limiting it to a very narrow range consistent with standard pharmaceutical manufacturing tolerances.

• The Term: "a suspending agent comprising..."

• Context and Importance: This phrase introduces the specific two-component suspending system that is a core element of the asserted independent claims. Its construction will determine whether the claim requires only the recited combination of xanthan gum and microcrystalline cellulose/sodium carboxymethylcellulose, or if other suspending agents could be present. If Aurobindo's formulation includes an additional suspending agent, the case could turn on whether "comprising" is interpreted as open-ended.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The term "comprising" is generally interpreted in patent law to be open-ended, meaning "including, but not limited to." The specification also lists numerous other examples of suitable suspending agents, which could support an argument that the inventors did not intend to limit the invention solely to the two agents listed in the claim '456 Patent, col. 4:49-61
  • Evidence for a Narrower Interpretation: A party may argue that the highly specific recitation of two distinct agents with specific concentration ranges represents a complete and essential definition of the suspending agent system for the claimed invention. This argument might suggest that while other agents are known, this particular combination is what confers patentability, thereby implicitly limiting the scope of the element.

VI. Other Allegations

• Indirect Infringement: The complaint alleges that Aurobindo had specific intent to infringe the patents when it filed its ANDA Compl. ¶34 Compl. ¶39 Compl. ¶44 It further alleges there are no substantial non-infringing uses for the Aurobindo ANDA Product, as it is a bioequivalent copy intended for the same therapeutic use, which supports a claim for induced infringement Compl. ¶34 Compl. ¶39 Compl. ¶44
• Willful Infringement: While the complaint does not explicitly use the term "willful," it alleges that Aurobindo had "actual and constructive knowledge" of the patents-in-suit prior to filing its ANDA and was aware that the filing constituted an act of infringement Compl. ¶34 Compl. ¶39 Compl. ¶44 Azurity also requests a finding that the case is "exceptional" under 35 U.S.C. § 285, which is the statutory basis for awarding attorneys' fees and is often associated with findings of willful infringement Compl., Prayer for Relief ¶e

VII. Analyst's Conclusion: Key Questions for the Case

This Hatch-Waxman action will likely center on the classic tension between a patented formulation and a proposed generic equivalent. The key questions for the court will be:

• A central issue will be one of definitional scope: can the term "about," as applied to the specific concentrations in the asserted claims, be construed to read on the precise formulation disclosed in Aurobindo's confidential ANDA, or will any deviation be sufficient to find non-infringement?
• The case will also present a core question of compositional identity: does Aurobindo's formulation contain the exact two-component suspending agent system recited in the claims, or does it use a different combination or include additional agents that might place it outside the literal scope of the claims, thus shifting the focus to the doctrine of equivalents?
• Finally, an underlying question, though not raised in the complaint, will be one of patent validity: can Aurobindo demonstrate by clear and convincing evidence that the claimed formulations, despite their specificity, were obvious or anticipated by the prior art related to liquid pharmaceutical suspensions at the time of the invention?